MedTrace Logo

Travoprost APS Versus Xalatan® in Patient Reported Outcomes and Ocular Surface Health

NCT00892762 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 434

Last updated 2014-07-15

No results posted yet for this study

Summary

The purpose of this study is to understand differences in visual function-related patient-reported outcomes between a non-BAK medication (Travoprost APS) and a BAK-preserved medication (XALATAN®) in patients with open-angle glaucoma or ocular hypertension.

Conditions

Interventions

DRUG

Travoprost APS 40 micrograms/ml eye drop solution

non-BAK (benzalkonium chloride) medication

DRUG

Latanoprost 50 micrograms/ml eye drop solution

BAK-preserved medication

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Theresa Landry, Ph.D. · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2011-05-31
Completion
2011-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00892762 on ClinicalTrials.gov